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The concept of drug discovery through stem cell biology is based on technological
developments whose genesis is now coincident. The ﬁrst is automated cell microscopy
with concurrent advances in image acquisition and analysis, known as high content
screening (HCS). The second is patient-derived stem cells for modeling the cell biology of
brain diseases. HCS has developed from the requirements of the pharmaceutical industry
for high throughput assays to screen thousands of chemical compounds in the search
for new drugs. HCS combines new ﬂuorescent probes with automated microscopy and
computational power to quantify the effects of compounds on cell functions. Stem cell
biology has advanced greatly since the discovery of genetic reprograming of somatic
cells into induced pluripotent stem cells (iPSCs). There is now a rush of papers describing
their generation from patients with various diseases of the nervous system. Although the
majority of these have been genetic diseases, iPSCs have been generated from patients
with complex diseases (schizophrenia and sporadic Parkinson’s disease). Some genetic
diseases are also modeled in embryonic stem cells (ESCs) generated from blastocysts
rejected during in vitro fertilization. Neural stem cells have been isolated from post-
mortem brain of Alzheimer’s patients and neural stem cells generated from biopsies of
the olfactory organ of patients is another approach.These “olfactory neurosphere-derived”
cells demonstrate robust disease-speciﬁc phenotypes in patients with schizophrenia and
Parkinson’s disease. HCS is already in use to ﬁnd small molecules for the generation and
differentiation of ESCs and iPSCs. The challenges for using stem cells for drug discovery
are to develop robust stem cell culture methods that meet the rigorous requirements for
repeatable, consistent quantities of deﬁned cell types at the industrial scale necessary
for HCS.
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INTRODUCTION
The last decades have seen development and applications in cellu-
lar neuroscience of DNA, RNA, and protein analysis technologies
that provide large volumes of information, getting away from
the traditional methods that follow the activities of single genes
or single cell types. The application of DNA sequencing, RNA
microarrays and higher throughput protein mass spectrometry
is allowing examination of biological systems in all their com-
plexity. What has been missing for cell biologists is the ability to
interrogate cell functions at the same scale and level of complex-
ity. This is being addressed by the developments in automated
technologies developed by pharmaceutical companies to screen
massive compound libraries for the discovery of new drug leads.
Until recently this high throughput screening, with robotic con-
trol and automated data capture and analysis of experiments in
96-, 384-, and 1,536-well plates, centered on enzyme and recep-
tor assays but increasingly, interest is turning to cell-based assays
that capture the complexity of the environment in which drugs
will actually operate. There has been a move to drug screening
based on cellular outcomes (e.g., cancer cell apoptosis, inhibi-
tion of growth) rather than predicted mechanism (e.g., enzyme
inhibition, receptor antagonism). This led to the concept and
development of “high content screening” (HCS) that combines
advances in ﬂuorescence labeling of cells, robotic and automated
microscopy, and automated image analysis that brings the analysis
of cell functions to the high throughput formats of multiwell plates
(Zanella et al., 2010). For the neuroscientist this technology opens
up new frontiers in the ability to manipulate many experimen-
tal variables simultaneously in highly controlled experiments. For
example, the effects of multiple drugs at multiple doses could be
tested simultaneously on several cell types.With themany ﬂuores-
cent reporter methods now available it is possible to follow three
or four cellular events in the same experiment in hundreds of cells
per well. With many well established platforms available, HCS
opens the door to neuroscience for large scale, high throughput
cell function analyses for understanding cell functions in health
and disease.
In neuroscience, the discovery of the genetic causes of familial
diseases has driven understanding of the functions of individ-
ual genes and proteins in cell function in the nervous system
and the effects of mutations on brain function. Identiﬁcation
of a candidate gene is followed by genetically modiﬁed cell and
Frontiers in Cellular Neuroscience www.frontiersin.org March 2013 | Volume 7 | Article 29 | 1
“fncel-07-00029” — 2013/3/25 — 20:40 — page 2 — #2
Mackay-Sim Stem cells and drug discovery
mouse models to identify the functions of the identiﬁed gene at
cell and systems level. Mouse models have been important for
elucidating protein and gene functions but they often do not
recapitulate human disease because the mice lack the human
genetic background and the introduced human genes are acting
in a non-human cellular context. Immortalized human cell lines
have a more relevant genetic background but, being derived from
tumors, they may not reﬂect a normal cellular context. Patient-
derived primary cells might be a solution for both drawbacks
but they cannot usually be maintained for very long in culture
and ﬁnding an accessible cell type for brain diseases is prob-
lematic. Stem cell technologies may have the solution to these
drawbacks.
There is an emerging interest in using stem cells to under-
stand the cellular bases of human diseases. There is an imperative
here, especially for neurological diseases and conditions. Large
pharmaceutical companies arewithdrawing from investing in neu-
roscience research because of the failure of the current paradigms
to convert ﬁndings in animal models to drugs for human dis-
ease (Schnabel, 2008). There are obviously many reasons why
animal models, genetic or otherwise, are not proving useful for
predicting human responses to drugs. On the other hand, there
are good reasons to expect that human stem cells might be useful,
if they can be derived from patients with a disease and, if they
are the cell types that are affected by the disease. This is clearly a
niche that stem cells have the developmental abilities to occupy.
Patient-derived stem cells could be used to identify cell functions
that are altered by disease and thereby provide a target for drug
discovery. Assays can then be developed forHCS to use the patient-
derived stem cells to screen large drug libraries for therapeutic
activity.
HIGH THROUGHPUT SCREENING
Increasingly in the last 20 years pharmaceutical companies have
developed high throughput technologies to screen large chemical
libraries of natural products and synthetic compounds for activi-
ties against selected enzymes and receptors, candidate targets for
diseases of interest (Macarron et al., 2011; Figure 1). These high
throughput technologies arose from the desire of pharmaceutical
companies to test all theoretical chemical compounds (∼100 mil-
lion) against all theoretical human biological targets, estimated
from the number genes (∼20,000) or proteins (∼200,000), indi-
cating that as many as 1012 assays would be needed to identify
all interactions between chemicals and targets (Sundberg, 2000).
These technologies are pharmacology on a large scale, initially
using 96-well plates and now routinely 384- and 1,536-well plates.
The imperative is to provide a means to screen very large com-
pound libraries in order to ﬁnd the very small percentage of lead
compounds that are active in a selected assay. High through-
put screening is historically based on solution based enzyme
and receptor assays using scintillation, absorbance, ﬂuorescence,
and chemiluminescence with the aim of ﬁnding highly speciﬁc
chemical interactions with individual biological targets (Sund-
berg, 2000). High throughput screening is also used in cell-based
assays, typically to monitor activation of cell surface receptors
through subsequent transduction pathways, transcription events,
cell proliferation, or cell death. These assays use multiwell plates
andmonitor colorimetric, ﬂuorescence, luminance, or absorbance
within each well. With developments in genetic technologies and
the understanding provided by theHumanGenomeProject, intra-
cellular events are available for high throughput screening through
the development genetic ﬂuorescent reporter assays. Cell lines
have genes for luminescent or ﬂuorescent proteins, like luciferase
or green ﬂuorescent protein (GFP), spliced into reporter sys-
tems to read out activation or inhibition of speciﬁc genes or
proteins of interest (Sundberg, 2000). High throughput technolo-
gies have advanced the development of robotic automation for
cell culture, assays, and compound library storage; automated
and multipurpose plate readers; ﬂuorescence dyes and reporter
systems; computational power, and automated data storage and
analysis. It currently takes about 1 week to screen 10,000 com-
pounds against a target and 1–3 months to screen a library of
onemillion compounds (Macarron et al., 2011). High throughput
screening has been successful in delivering numerous drugs from
discovery through to clinical use and the market starting from
chemical libraries of 200,000–500,000 compounds (Macarron
et al., 2011).
HIGH CONTENT SCREENING
High content screening is a further development in which the
principles of high throughput screening are applied to the analysis
of individual cells through the use of automated microscopy and
image analysis (Zanella et al., 2010; Figure 2). This allows quan-
titative analyses of components of cells such as spatio-temporal
distributions of individual proteins, cytoskeletal structures, vesi-
cles, and organelles when challenged with chemical compounds.
HCS can be used to monitor activation or inhibition of individual
proteins and protein–protein interactions as well as allowing anal-
ysis of broader changes in biological processes and cell functions.
Recent advances in the range of ﬂuorescent probes for biolog-
ical processes, functions, and cell components have combined
with developments in ﬂuorescence microscopy to give the cell
biologists many new ways to understand cell functions in health
and disease. These cell-centric developments have converged with
high throughput concepts and with developments in automated
microscopy and image analysis to evolve into thenew technological
synthesis of high throughput screening in which cell-based assays
are conducted in multiwell plate formats. High content technolo-
gies are now used to screen chemical libraries for drug discovery
as well as genome-wide RNA interference libraries to probe gene
functions (Zanella et al., 2010). One of the advantages of HCS is
the ability to apply different criteria to selected cells in the popu-
lation to account for the heterogeneity of the cell population. For
example, a chemical compound of interfering RNA may only act
on cells in a particular stage of the cell cycle.Well-based assays pro-
vide a readout from the whole cell population, a mixture of cells
in different phases of the cell cycle, whereas with cell-based HCS
and appropriate markers, cells at identiﬁed phases of the cell cycle
could be assessed independently. Thus HCS allows quantitative
analysis of complex and heterogeneous cell cultures containing
multiple cell types. Another advantage of HCS technologies is the
ability to make multiple independent and quantitative measure-
ments from single cells of interest. For example, transmitted light
might be used to assess morphology; three or more ﬂuorophores
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FIGURE 1 | High throughput screening: industrial scale biology. High
throughput screening is an automated process for conducting thousands of
assays to identify active molecules modulating a biomolecular activity. Assays
are performed in multiwell plates with robotics for cell and liquid handling and
other aspects such as moving plates from incubator to drug delivery to plate
reader. An assay for a cell function of interest must be validated for multiwell
plate readers, such as ﬂuorescence, absorbance, or luminescence. Here the
assay is a ﬂuorescence assay (Cyquant) for cell number. High levels of quality
assurance and quality control are required to reduce the variance of the
measurement so that the assay can be reliably scaled to multiple plates.
Typically, thousands of compounds are screened for activity, with “hits” being
deﬁned as those compounds whose activity on the assay falls outside three
standard deviations (red lines) around the mean of the controls on the plate
(blue dots). Hits are the gray dots above and below the red lines. Secondary
screens are then used to validate the initial hits. These screens may include
dose–response curves or assays of related functions of interest, resulting in a
selection of “validated hits,” which may comprise fewer than 1% of a typical
library of compounds of varied structure. Here the validated hits are the
numbered dots above the red line. Validated hits are then further assayed and
modiﬁed chemically in an iterative process to improve potency, selectivity,
pharmacological properties, and toxicological proﬁle to produce a drug lead
compound that will go into “preclinical” testing in animal models. High
throughput screening is applied to large libraries of any potentially bioactive
molecules including natural products, small molecule drugs, RNAs, and DNAs.
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FIGURE 2 | High content screening: industrial scale microscopy. High
content screening is the automated microscopic analysis of ﬂuorescence in
cells of a multiwell plate. Most high throughput screening assays read
activity per well (e.g., ﬂuorescence, absorbance, and luminescence). In
high content screening ﬂuorescence in individual cells is quantiﬁed with
automated image analysis. Typically, algorithms ﬁnd the cells in the image
and then measure ﬂuorescence intensity and spatial distribution. The
example shows tubulin ﬂuorescence in cells (green) and cell nuclei (blue) at
different concentrations of taxol, a tubulin-binding drug. The drug effect is
difﬁcult to see by eye but the analysis algorithm identiﬁes each cell and
quantiﬁes tubulin ﬂuorescence intensity, plotted here as a dose–response
curve to two drugs, taxol (blue) and vinblastine (red) in two cell types:
control-derived ONS cells (solid lines) and HSP patient-derived ONS cells
(dashed lines; Abrahamsen et al., 2013). With high content screening
thousands of cells can be analyzed to reveal small but signiﬁcant
differences between drugs, doses, and cell types.
might be used to identify molecular components, structures,
or organelles; and image analysis might be used to quantify
spatial relationships between the ﬂuorescent reporters under con-
trol conditions or when challenged with chemical compounds.
With assays performed in multiwell plates there is opportunity
to scale up experiments to include replicates, concentration–
response curves, and parallel assessments of different cells or
compounds. Modern instruments equipped with incubators and
confocal optics have the ability to investigate cells over time in three
spatial dimensions. These technologies will advance further and
become cheaper allowing HCS principles to be applied increas-
ingly by academic labs and not restricted to large pharmaceutical
companies.
In the neurosciences, there is now an opportunity and chal-
lenge to combine patient-derived, disease-speciﬁc stem cells with
HCS technologies with the aim of ﬁnding new drugs for brain
diseases and conditions. This is not a simple aspiration because
the majority of brain diseases are a result of complex genetic and
environmental risk factors. Furthermore, brain diseases are usu-
ally just that, “brain” diseases and not “cell” diseases in the sense
that cancers are. Nonetheless, it is possible that most brain dis-
eases result from identiﬁable cellular dysfunctions such as those
identiﬁed in monogenic disease. Such mutations tell us that spe-
ciﬁc brain dysfunctions can be manifest in speciﬁc cell types and
pathways, despite universal genetic mutation. This gives hope that
cellularmodels will shed light on themolecular and cellularmech-
anisms of emergent properties (e.g., cognition, emotion) evident
when the brain functions as a whole.
DISEASE-SPECIFIC PLURIPOTENT STEM CELL MODELS OF
NEUROLOGICAL DISEASE
The analysis of gene function through gain- or loss-of-function
in cell, ﬂy, and mouse models has been very instructive in elu-
cidating functions of genes and proteins but less successful in
providing models that predict drug efﬁcacy in human diseases.
An example is the failure of the superoxide dismutase trans-
genic mouse model for amyotrophic lateral sclerosis that has
yielded multiple compounds that are therapeutic in mouse but
not humans (e.g., creatine; Klivenyi et al., 1999; Groeneveld et al.,
2003). These problems arise because of species and model differ-
ences which do not mimic gene dosage, gene mutation variability
or genetic background, or the complex of other contributing
genetic factors that will be present in individuals with a disease.
Patient-derived cells provide a potential solution to some of these
problems because they reﬂect the genetic background and vari-
ation of the human population, arising from individuals with
natural mutations. Sources of patient-derived cells have included
easily accessible ﬁbroblasts and lymphocytes and lymphoblastoid
cell lines but there is concern that these cells will not manifest the
same disease-associated properties as the cells speciﬁcally dysfunc-
tional in the disease of interest, for example dopaminergic neurons
of the substantia nigra in Parkinson’s disease or oligodendrocytes
in multiple sclerosis. For such cell type-speciﬁcity the ﬁeld holds
high hopes of pluripotent stem cells which can theoretically be
induced to differentiate into any cell type of interest.
Disease-speciﬁc pluripotent stem cells include human embry-
onic stem cells (ESCs) with genetic or chromosomal disorders
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derived from surplus blastocysts during in vitro fertilization
and pre-implantation genetic diagnosis (Stefanova et al., 2012).
Although these are not strictly “patient-derived” they carry spe-
ciﬁc genetic mutations or deletions that would normally lead to
disease. Induced pluripotent stem cells (iPSCs) from patients have
become the dominant choice for patient-derived pluripotent stem
cells. A recent review lists 18 diseases for which ESCs have been
derived, compared with 40 for which iPSCs have been derived
(Grskovic et al., 2011). At this timemany of the publications in this
ﬁeld are mainly demonstrations that pluripotent stem cells have
been derived, often without demonstrating a disease-phenotype.
Some show that the pluripotent cells can be differentiated into
speciﬁc cell types of interest and some demonstrate deﬁcits in cel-
lular functions compared to control cells, as proof-of-principle
for disease modeling (Grskovic et al., 2011; Maury et al., 2012).
No doubt the numbers of diseases for which iPSCs are available
will increase greatly in the next few years and deeper analyses of
their functions will be forthcoming. It is a major challenge for
the ﬁeld to move beyond the proof-of-principle stage to discovery
of new aspects of disease biology and new targets for therapeutic
intervention.
The list of neurological diseases and conditions for which
ESCs or iPSCs have been derived is largely limited to monogenic
diseases including Charcot–Marie–Tooth disease type 1A, Down
syndrome-trisomy21, familial amyotrophic lateral sclerosis, famil-
ial dysautonomia, familial Parkinson’s disease, FragileX syndrome,
Friedreich ataxia, Gaucher’s disease, Huntington’s disease, Rett
syndrome, Spinal muscular atrophy, spinocerebellar ataxia types 2
and 7, and X-linked adrenoleukodystrophy (Grskovic et al., 2011;
Maury et al., 2012; Rajamohan et al., 2013). It is thought that dis-
eases of complex genetics and environmental risk factors may be
harder to model with pluripotent stem cells but patient-derived
iPSCs have been generated from patients with Parkinson’s disease
(Soldner et al., 2009) and schizophrenia (Brennand et al., 2011;
Pedrosa et al., 2011). Patient-derived iPSCs from people with spo-
radic Parkinson’s disease were differentiated into dopaminergic
neurons but failed to show an obvious difference in pheno-
type compared to control cells (Soldner et al., 2009). Similarly, a
disease-associated phenotype could not be demonstrated in iPSCs
from two cases of sporadic Alzheimer’s disease (Israel et al., 2012).
In one study, iPSCs from schizophrenia patients were differenti-
ated into neurons and gene expression proﬁling identiﬁed a cluster
of differentially expressed genes involved in neurogenesis, neu-
ronal differentiation, axon guidance, and adhesion with another
cluster of differentially expressed genes involved in cell cycle reg-
ulation (Pedrosa et al., 2011). A second study in schizophrenia
showed that neurons differentiated from patient-derived iPSCs
had reduced neurite number and reduced connectivity with other
neurons in vitro and reduced glutamate receptor expression (Bren-
nand et al., 2011). These studies of patient-derived iPSCs from
schizophrenia patients demonstrate that such models can reveal
disease-associated cellular deﬁcits in a disease of complex genet-
ics, although the patients were all from families with psychosis,
rather than sporadic cases.
It is a challenge to translate pluripotent cells into robust dis-
ease models (Maury et al., 2012). For example, ESCs are limited
by the availability of genetic testing and pre-implantation genetic
diagnosis. For their part, iPSCs are potentially compromised by
the methods of their generation; most cell lines published to date
were produced by integrating vectors, although this will change
as the efﬁciency and predictability of non-integrating methods
improves. There are other technical challenges for disease mod-
eling such as the current lack of robust and efﬁcient protocols
for differentiating ESCs and iPSCs into disease-associated cells of
interest. Attention is drawn to the importance of selecting appro-
priatematched controls because case–control cell differences could
arise from sampling bias and “disease-associated” differences may
result from particular comparator control cells (Zhu et al., 2011;
Maury et al., 2012). This difﬁculty is compounded by the large
cost of generation and maintenance of ESCs and iPSCs that will
limit sample sizes for most laboratories. One preferred method
would be to use each patient-derived cell line as its own con-
trol by correcting its genetic defect (Zhu et al., 2011; Maury et al.,
2012) but this is possible only in the monogenic disease cases of
known mutations that can be selectively corrected. It is expected
that many of these challenges will be overcome as new method-
ologies develop for efﬁcient production of patient-derived iPSCs
that are generated with non-integrating reprograming methods
(Grskovic et al., 2011) and efﬁcient methods are devised for differ-
entiation into desired cell types: speciﬁc neurons, astrocytes, and
oligodendrocytes.
PATIENT-DERIVED OLFACTORY STEM CELLS AS MODELS FOR
NEUROLOGICAL DISEASES
Published studies of ESCs and iPSCs as disease models are all
conﬁned to small numbers of cell lines from patients and con-
trols. This makes it difﬁcult to generalize from these case–control
studies to the general population. Variability in the reprogram-
ing process and epigenetic status makes it essential that several
clones from several individuals are compared to conﬁrm that a
“disease-phenotype” is not confounded by individual differences
among case or control cell lines (Vitale et al., 2012). Ideally, patient-
and control-derived cells should be sampled from large popu-
lations to be certain that differences between the samples are
representative of the population. In the case of genetic diseases
with high penetrance of the clinical phenotype, the case–control
design may be robust to small sample size but this may not be
true of lower penetrance phenotypes, or of sporadic diseases of
complex genetics. This sampling problem can be overcome with
accessible cells that can be derived easily from larger numbers of
individuals, such as patient-derived ﬁbroblasts and lymphocytes,
which have been used to identify potential cellular mechanisms or
biomarkers of neurological diseases including Alzheimer’s disease
(Takahashi et al., 1999; Moreira et al., 2007), Parkinson’s disease
(Martin et al., 1996;Hoepken et al., 2008), and schizophrenia (Ilani
et al., 2001; Wang et al., 2010). Although these cell types have
identiﬁed cellular and molecular differences between patients and
controls, their relevance to diseases of the nervous system is moot
and the patient–control differences can be non-existent (Matigian
et al., 2008).
Another approach to modeling diseases is to sample patient-
derived adult stem cells. Neural progenitor cells were isolated from
post-mortembrain fromAlzheimer’s patients and healthy controls
(Lovell et al., 2006). Mesenchymal stem cells were isolated from
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controls and patients with amyotrophic lateral sclerosis (Ferrero
et al., 2008) and Parkinson’s disease (Zhang et al., 2008). None
of these studies reported disease-associated differences, on the
contrary all stated that patient and control cells were of similar
phenotype.
There is a multipotent adult stem cell resident in the olfactory
mucosa, the organof smell in thenose (Murrell et al., 2005). A stem
cell in the olfactory epitheliummaintains a continual neurogenesis
throughout life that regenerates the sensory neurons (Mackay-Sim
and Kittel, 1991a,b; Murrell et al., 1996). Olfactory epithelium is
one of the few places in the nervous system that contains a neural
stem cell but, unlike the other sites in the brain, it is accessible
under local anesthetic (Feron et al., 1998) and several studies have
shown disease-associated differences in cell biology in this tis-
sue. Olfactory neuroblasts isolated from post-mortem epithelial
biopsies from controls and individuals with Alzheimer’s disease
demonstrated differences in amyloid precursor protein process-
ing (Wolozin et al., 1993) and oxidative stress (Ghanbari et al.,
2004). Histological analysis of olfactory epithelium indicates dis-
turbed neural differentiation in schizophrenia (Arnold et al., 2001)
and Rett syndrome (Ronnett et al., 2003). Cultures of olfactory
mucosa show increased cell proliferation and reduced tissue adhe-
sion in schizophrenia compared to healthy controls (Feron et al.,
1999; McCurdy et al., 2006). Clearly the olfactory organ demon-
strates disease-associated differences in cell biology in several brain
diseases including amonogenic disease (Rett syndrome) and com-
plex genetic diseases of no known genetic cause (Alzheimer’s
disease and schizophrenia). This led to the development of an
olfactory stem cell-based system for investigating brain diseases
based on olfactory neurosphere-derived cells (ONS cells; Matigian
et al., 2010).
The olfactory mucosa comprises the superﬁcial epithelium
and the underlying lamina propria separated by a basement
membrane. Within the epithelium are basal cells among which
are the multipotent stem cells that can regenerate all the cell
types of the epithelium including the sensory neurons as well
as other non-neural supporting and gland cells (Leung et al.,
2007; Packard et al., 2011). Within the human lamina propria
is a multipotent stem cell with characteristics both of neural and
mesenchymal stem cells, an ectomesenchymal stem cell (Delorme
et al., 2010). The lineage relation between these stem cells, if any,
is not known. When biopsies of human olfactory mucosa are
dissociated and grown in a serum-free medium containing epi-
dermal growth factor (EGF) and basic ﬁbroblast growth factor 2
(FGF2), neurospheres form that can differentiate into neu-
rons and glia and cells of non-ectodermal lineage, including
developing cardiac and skeletal muscle, kidney and liver, and
blood (Murrell et al., 2005). Neurospheres are dissociated and
when the cells are grown as adherent cultures in a serum-
containingmedium, these“neurosphere-derived”cells (ONS cells)
have a ﬂattened, undifferentiated appearance with a marker
phenotype similar to the ectomesenchymal cells derived from
primary cultures of olfactory mucosa (Delorme et al., 2010;
Matigian et al., 2010), that is, they express markers of both neu-
ral and mesenchymal lineages. Patient-derived ONS cells show
robust disease-speciﬁc differences compared to ONS cells derived
from healthy controls (Mackay-Sim, 2012). Gene expression
proﬁling of ONS cells from healthy controls and patients with
Parkinson’s disease or schizophrenia showed disease-speciﬁc dif-
ferences in gene expression, protein expression, and cell functions
(Matigian et al., 2010). Disease-associated gene expression differ-
enceswere quite different in schizophrenia andParkinson’s disease,
with alterations in neurodevelopmental pathways in schizophre-
nia and in oxidative stress and metabolic function in Parkinson’s
disease (Matigian et al., 2010). Deeper analysis of the gene expres-
sion showed disease-speciﬁc differences in the variance of gene
expression in the major signaling pathways. Overall schizophrenia
patient-derived ONS cells were less variant in their gene expres-
sion compared to controls whereas Parkinson’s patient-derived
ONS cells were more variant than controls, indicating another
dimension along which diseases can affect cell functions (Mar
et al., 2011).
Parkinson’s patient-derived ONS cells showed gene expression
and functional differences indicating dysfunctions in pathways
involvedmitochondrialmetabolism andoxidative stress (Matigian
et al., 2010). Pathway analysis of the gene expression differences
found that the antioxidative nuclear factor (erythroid-derived 2)-
like 2 (NRF2) signaling pathway was overrepresented among the
dysregulated genes (Matigian et al., 2010). NRF2 is a transcrip-
tion factor that ameliorates the effects of oxidative stress. Deeper
analysis of the ONS cells demonstrated that the NRF2 signal-
ing pathway was dysfunctional: although the NRF2 protein was
equally expressed in patient and control cells the downstream
targets of NRF2 were reduced, suggesting lesser activation of
NRF2 signaling in the patient cells (Cook et al., 2011). In contrast,
schizophrenia patient-derived ONS cells showed gene expression
and functional differences indicating dysfunctions in pathways
involved neurodevelopment (Matigian et al., 2010). Pathway anal-
ysis of the gene expression differences identiﬁed aspects of the cell
cycle that were dysregulated, in particular G1/S phase transition,
the check point in cells that controls the beginning of DNA synthe-
sis (Matigian et al., 2010). Functional analysis demonstrated that
patient-derived cells proliferated faster than control-derived cells
in accord with previous observations in olfactory biopsy cultures
(Feron et al., 1999; McCurdy et al., 2006). This faster rate of cell
proliferation was due to a 2-h shorter cell cycle period in patient
cells (Fan et al., 2012). G1/S phase transition is dependent on the
intracellular levels of cyclin D1, a cell cycle control protein; cyclin
D1 levels were elevated in patient cells and reached higher levels
more quickly than control cells (Fan et al., 2012). In schizophre-
nia, ONS cells gene expression was signiﬁcantly dysregulated in
the focal adhesion kinase signaling pathway, which is involved in
regulating attachment to the extracellular matrix through cell sur-
face integrin receptors (Fan et al., 2013). Functional analyses of
the patient-derived cells showed they were less adhesive and more
motile than control-derived cells with smaller and fewer sites of
adhesion that disassembled more quickly than in control-derived
cells (Fan et al., 2013). These studies demonstrate that patient-
derived ONS cells can show robust disease-speciﬁc differences in
cell biology even in sporadic diseases of complex genetics.
Olfactory neurosphere-derived cells are also proving useful for
understanding monogenic diseases. Hereditary spastic paraple-
gia (HSP) is an autosomal dominant disease affecting the long
spinal axons from the motor cortex to the lower motor neurons
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in the spinal cord. ONS cells from patients with HSP were simi-
lar in many basic cell functions to ONS cells from healthy controls
despite dysregulation of expression of 60%of the genome, indicat-
ing a high level of homeostatic regulation in response to dominant
mutations in SPAST, which codes for a microtubule severing pro-
tein (Abrahamsen et al., 2013). Closer inspection of cell functions
using HCS revealed signiﬁcant reductions in stable microtubules
and in the intracellular distributions of peroxisomes and mito-
chondria (Abrahamsen et al., 2013). Live-cell time-lapse imaging
revealed that peroxisomes traveled more slowly in HSP patient-
derived cells, consistent with the corticospinal axon pathology in
HSP (Abrahamsen et al., 2013). Ataxia telangiectasia (AT) is a fatal
autosomal recessive disease characterized by radiation sensitivity,
cancer, and cerebellar dysfunction. ONS cells from children with
AT had radiation sensitivity andDNA-repair deﬁcits that were cor-
rected by insertion of the full-length gene (Stewart et al., 2013).
Immature neurons from AT patient-derived ONS cells showed
evidence of impaired differentiation (Stewart et al., 2013). Olfac-
tory ectomesenchymal stem cells, similar to ONS cells, demon-
strated a disease-associated effect of mis-splicing of the IKBKAP
gene leading to reduced levels of IKBKAP protein and altered
cell migration in patient-derived cells in familial dysautonomia
(Boone et al., 2010).
PATIENT-DERIVED OLFACTORY STEM CELLS FOR DRUG
DISCOVERY
Patient-derived ONS cells have several advantages for HCS for
drug lead identiﬁcation. They are cheap to grow and maintain,
growing in standard cell culture conditions with no expensive
growth factors after the neurosphere-forming stage. As ONS cells
they can be grown for at least 16 passages without signiﬁcant
change in gene expression thus demonstrating minimal phe-
notypic change and without change in karyotype (unpublished
observations). ONS cells are derived from neural tissue and can
obviously show disease-speciﬁc phenotypes relevant to the neuro-
logical diseases from which the donors suffer. Proof-of-principle
analyses have shown that brain diseases “in a dish” can be amelio-
rated by drug treatment. For example, Parkinson’s patient-derived
ONS cell functions were restored to control-derived cell levels
by treatment with L-sulforaphane, an agonist of NRF2 (Cook
et al., 2011). Similarly, a small molecule drug kinetin was able to
reverse themis-splicing of the IKBKAP gene in familial dysautono-
mia patient-derived ectomesenchymal cells (Boone et al., 2010) as
it has in iPSCs from these patients (Lee et al., 2009). HCS was
used to test the differential sensitivity of HSP patient-derived and
control-derived ONS cells to the tubulin-binding drugs, taxol and
vinblastine (Abrahamsen et al., 2013). HSP patient-derived cells
had 50% the control level of spastin, a tubulin-severing enzyme,
150% of the control level of stathmin, a tubulin depolymeriz-
ing enzyme, and 50% of the control level of acetylated a-tubulin,
an indicator of stabilized microtubules (Abrahamsen et al., 2013).
HCS showed that patient-derived and control-derived ONS cells
were highly sensitive to the drugs, with effects at 0.1 nM (Figure 2).
Both drugs increased acetylated a-tubulin, but with different
dose–response curves, and low doses of both drugs (∼0.3 nM)
restored patient cell acetylated a-tubulin to the control cell level
(Abrahamsen et al., 2013).
These experiments show that disease-associated dysfunctions
in olfactory cells can be ameliorated by candidate chemical
compounds acting on targets known to be disrupted in the patient-
derived cells compared to controls. The next challenge is to see
whetherONS cells are useful for screening libraries of compounds.
They have some of the necessary characteristics such as ease of
generation, low cost, robust and repeatable growth characteristics
and predictable phenotype. These properties make them useful
for building up banks of cells that will allow assessment of vari-
ability of cell biology across a wider population of patients and
controls, to discriminate disease-speciﬁc differences from individ-
ual differences in complex diseases like Parkinson’s disease and
schizophrenia.
FUTURE PROSPECTS
One of the challenges for the ﬁeld is to develop robust and
repeatable protocols for producing the large quantities of speciﬁed
neurons or glia that are required for high throughput screening.
For ESCs and iPSCs differentiating protocols exist for making dif-
ferent types of neurons, such as dopaminergic neurons, cortical
neurons, and motor neurons (Chambers et al., 2009) but the yield
is generally low and variable. This is not necessarily limiting for
low-throughput investigations of disease-associated cell pheno-
types and lead validation but is certainly limiting for primary drug
screens. ONS cell production is not limiting for drug discovery but
they currently also lack robust and repeatable protocols for differ-
entiating themondemand intoneurons and glia in vitro. In growth
factor-free medium 50% of the cells were “astrocytes” [glial ﬁbril-
lary acidic protein (GFAP)-positive cells], a proportion elevated
by ciliary neurotrophic factor (Murrell et al., 2005). “Neurons”
(β-tubulin-III-positive cells) were less frequent but rose to 25% of
the population with nerve growth factor in the medium. (Murrell
et al., 2005). Retinoic acid induced amajority (50%)of O4-positive
“oligodendrocytes” (Murrell et al., 2005). ONS cell differentiation
was deﬁned in terms of morphology and immunoﬂuorescence
and so lacks the deﬁnitive demonstration of differentiation shown
repeatedly for ESCs and IPSCs.
The concept of drug discovery through patient-derived stem
cell models of brain diseases is attractive but has many other
challenges apart from the practical issues of cost and reliable pro-
duction. Concerns are raised about the epigenetic status of iPSCs
and ESCs – epigenetic status is variably altered by reprograming
and by culture methods (Stadtfeld and Hochedlinger, 2010) hence
diseases in which epigenetics plays a role may not be modeled well
by iPSCs and ESCs (Zhu et al., 2011; Maury et al., 2012). There
is not yet a consensus about which cell type is the best for repro-
graming (Stadtfeld and Hochedlinger, 2010) or which method
of reprograming is the most robust and reliable (Grskovic et al.,
2011). Differentiation of human iPSCs is not yet routine and pre-
dictable and can take many weeks (Grskovic et al., 2011). There
is discussion about the applicability of iPSCs to model late-onset
diseases like Parkinson’s disease or Alzheimer’s disease, with the
inference that iPSCs may be better suited to neurodevelopmen-
tal disease modeling (Juopperi et al., 2011). Olfactory stem cell
models appear to be suited to late-onset and sporadic diseases
perhaps because they are not subject to the genetic and epigenetic
changes due to reprograming. Olfactory stem cells are relatively
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FIGURE 3 | Choices of stem cells to model brain diseases. Different
criteria guide choices of cells to model brain diseases. ESCs derived during
pre-implantation genetic diagnosis are useful for monogenic diseases.
Patient-derived adult cells are useful for genetic and sporadic diseases, with
the advantage of an associated clinical history. ESCs and iPSCs take many
months to generate, validate, and then to produce neurons and glia but have
the advantage of being highly proliferative and pluripotent. iPSCs and induced
neurons require reprograming with genes, proteins or drugs, whereas ESCs
and ONS cells do not. ONS cells and induced neurons may retain the
methylation status of differentiated cells whereas ESCs and iPSCs do not. All
methods introduce variability associated with cell culture but iPSCs and
induced neurons may be more variable because of clonal selection due to the
low efﬁciencies of the induction processes. ESC and ONS cell production
average inter-clonal variation across large populations.
inexpensive and can be reliably grown in large quantities but they
also suffer from difﬁculties in robust and routine differentiation
protocols. As more diseases get modeled by iPSCs and ONS cells
the strengths and weaknesses of each model will be determined
for speciﬁc applications and the relevance of each model to the
disease of interest will be determined. The use of particular cell
models for drug discovery will depend on many variables includ-
ing relevance to the disease, ease and cost of use, and stage of the
drug discovery process (Figure 3). These questions and challenges
are all signs of a ﬁeld at the very beginning of its genesis and many
will undoubtedly be resolved in the coming years.
Other developments in reprograming will affect this future.
It is now possible to generate neurons directly from skin ﬁbrob-
lasts (Vierbuchen et al., 2010). This may greatly reduce the cost
of producing patient-derived neurons for drug discovery because
ﬁbroblasts, like ONS cells are cheaper to generate, expand, and
maintain than iPSCs. Through similar direct reprograming it
may be possible to on demand speciﬁc classes of neurons, astro-
cytes, and oligodendrocytes. Ultimately whether any of these
new technologies reach routine application in drug discovery will
depend on cost, robustness, and industrial scalability as well as the
biological validity of the cells as disease models.
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